Buruli ulcer is also called as Mycobacterium Ulcerans Infection. It is a chronic debilitating disease caused by environmental Mycobacterium Ulcerans. This infection affects the skin and sometime bone and can lead to permanent disfigurement and long-term disability.
The increase in incidence of Buruli Ulcers is the key driving factor for market which expected to boost the global Buruli ulcer treatment market growth. According to World Health Organization Buruli ulcer has been reported in 33 countries including Asia, Africa etc. In Africa, many cases are reported from west and Central Africa, including Cameroom, Bennin, Ghana and Nigeria. In Ghana, the Buruli Ulcer cases has been reported to be as high as 150.8/100,000 and in Southern Benin 21.5/100,000 every year. It is higher than tuberculosis or leprosy.Furthermore, increase in demand for mycobacterial drugs as well as rise in awareness regarding surgery in patients will positively contribute the market growth. Moreover, availability of effective treatment with skilled surgery, therapeutic physiotherapy, and expert nursing care expected to global Buruli ulcer treatment cancer market growth.
However, high cost of surgery is the major challenging factor which is expected to hinder the global buruli ulcer market growth. Also, nonappearance of conclusive treatment, restricted adequacy of the indications will affect the market growth.
Global Buruli Ulcer Treatment Market is segmented into treatment such as Antibiotics (Rifampicin, Streptomycin, Amikacin, Clarithromycin, Moxifloxacin, and Others), Surgery (Skin Grafting, and Others). Further, market is segmented into distribution channel such as Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics, and Others.
Also, Global Buruli Ulcer Treatment Market is segmented into is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Various key players are discussed in this report such as Pfizer, GlaxoSmithKline plc., B Braun, Cipla Limited, Perk Pharmaceuticals Ltd, Lupin Laboratories Ltd, Teva Pharmaceuticals, Novartis, AbbVie Inc, Bayer Healthcare, Dr. Reddys Labs, and Mylan Pharms Inc.
Antibiotics Surgery
By Antibiotics Rifampicin Streptomycin Amikacin Clarithromycin Moxifloxacin Other
By Surgery Skin Grafting Others
By Distribution Channel Hospital Pharmacies Drug Stores Retail Pharmacies Clinics Others
North America
Latin America
Europe Asia Pacific
Middle East & Africa
Opportunities in Global Buruli Ulcer Treatment Market?
What will be the growth rate from 2023 to 2030?
Which segment/region will have highest growth?
What are the factors that will impact/drive the Market?
What is the competitive Landscape in the Industry?
What is the role of key players in the value chain?
What are the strategies adopted by key players?
Global Buruli Ulcer Treatment Market TOC
1 Introduction 1.1 Objective of the Study 1.2 Market definition 1.3 Market Scope
2 Research Methodology
2.1 Data Mining 2.2 Validation 2.3 Primary Interviews 2.4 List of Data Sources
3 Executive Summary 4 Global Buruli Ulcer Treatment Market Outlook 4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis
5 Global Buruli Ulcer Treatment Market, By Treatment 5.1 Y-o-Y Growth Comparison, By Treatment
5.2 Global Buruli Ulcer Treatment Market Share Analysis, By Treatment
5.3 Global Buruli Ulcer Treatment Market Size and Forecast, By Treatment 5.3.1 Antibiotics 5.3.2 Surgery
6 Global Buruli Ulcer Treatment Market, By Antibiotics 6.1 Y-o-Y Growth Comparison, By Antibiotics
6.2 Global Buruli Ulcer Treatment Market Share Analysis, By Antibiotics
6.3 Global Buruli Ulcer Treatment Market Size and Forecast, By Antibiotics 6.3.1 Rifampcin 6.3.2 Streptomycin
6.3.3 Amikacin
6.3.4 Clarithromycin
6.3.5 Moxifloxacin
6.3.6 Others 7 Global Buruli Ulcer Treatment Market, By Surgery 7.1 Y-o-Y Growth Comparison, By Surgery
7.2 Global Buruli Ulcer Treatment Market Share Analysis, By Surgery
7.3 Global Buruli Ulcer Treatment Market Size and Forecast, By Surgery 7.3.1Skin Grafting 7.3.2 Others 8 Global Buruli Ulcer Treatment Market, By Distribution Channel 8.1 Y-o-Y Growth Comparison, By Distribution Channel
8.2 Global Buruli Ulcer Treatment Market Share Analysis, By Distribution Channel
8.3 Global Buruli Ulcer Treatment Market Size and Forecast, By Distribution Channel 8.3.1 Hospital Pharmacies
8.3.2 Drug Stores 8.3.3 Retail Pharmacies
8.3.4 Clinics
8.3.5 Others 9Global Buruli Ulcer Treatment Market, By Region 9.1 Global Buruli Ulcer Treatment Market Share Analysis, By Region
9.2 Global Buruli Ulcer Treatment Market Share Analysis, By Region
9.3 Global Buruli Ulcer Treatment Market Size and Forecast, By Region
10 North America Buruli Ulcer Treatment Analysis and Forecast (2020 – 2027) 10.1 Introduction
10.2 North America Buruli Ulcer Treatment Product Market Share Analysis, By Treatment
10.3 North America Buruli Ulcer Treatment Product Market Size and Forecast, By Antibiotics
10.4 North America Buruli Ulcer Treatment Product Market Size and Forecast, By Surgery
10.5 North America Buruli Ulcer Treatment Product Market Size and Forecast, By Distribution Channel
10.6 North America Buruli Ulcer Treatment Product Market Size and Forecast, By Country
10.6.1 U.S. 10.6.2 Canada 10.6.3 Mexico
11Europe Buruli Ulcer Treatment Market Analysis and Forecast (2023 – 2030) 11.1 Introduction
11.2 Europe Buruli Ulcer Treatment Product Market Share Analysis, By Treatment
11.3 Europe Buruli Ulcer Treatment Product Market Size and Forecast, By Antibiotics
11.4 Europe Buruli Ulcer Treatment Product Market Size and Forecast, By Surgery
11.5 Europe Buruli Ulcer Treatment Product Market Size and Forecast, By Distribution Channel
11.6 Europe Buruli Ulcer Treatment Product Market Size and Forecast, By Country
11.6.1 Germany 11.6.2 France 11.6.3 UK
11.64. Rest of Europe
12Asia Pacific Buruli Ulcer Treatment Market Analysis and Forecast (2023 – 2030) 12.1 Introduction
12.2 Asia Pacific Buruli Ulcer Treatment Product Market Share Analysis, By Treatment
12.3 Asia Pacific Buruli Ulcer Treatment Product Market Size and Forecast, By Antibiotics
12.4 Asia Pacific Buruli Ulcer Treatment Product Market Size and Forecast, By Surgery
12.5 Asia Pacific Buruli Ulcer Treatment Product Market Size and Forecast, By Distribution Channel
12.6 Asia Pacific Buruli Ulcer Treatment Product Market Size and Forecast, By Country
12.6.1 China 12.6.2 Japan 12.6.3 India
12.6.4. Rest of Asia Pacific
13Latin America Buruli Ulcer Treatment Market Analysis and Forecast (2023 – 2030) 13.1 Introduction
13.2 Latin America Buruli Ulcer Treatment Product Market Share Analysis, By Treatment
13.3 Latin America Buruli Ulcer Treatment Product Market Size and Forecast, By Antibiotics
13.4 Latin America Buruli Ulcer Treatment Product Market Size and Forecast, By Surgery
13.5 Latin America Buruli Ulcer Treatment Product Market Size and Forecast, By Distribution Channel
13.6 Latin America Buruli Ulcer Treatment Product Market Size and Forecast, By Country
14Middle East Buruli Ulcer Treatment Market Analysis and Forecast (2023 – 2030) 14.1 Introduction
14.2 Middle East Buruli Ulcer Treatment Product Market Share Analysis, By Treatment
14.3 Middle East Buruli Ulcer Treatment Product Market Size and Forecast, By Antibiotics
14.4 Middle East Buruli Ulcer Treatment Product Market Size and Forecast, By Surgery
14.5 Middle East Buruli Ulcer Treatment Product Market Size and Forecast, By Distribution Channel
14.6 Middle East Buruli Ulcer Treatment Product Market Size and Forecast, By Country
15Competitive Analysis 15.1 Competition Dashboard 15.2 Market share Analysis of Top Vendors 15.3 Key Development Strategies
16Company Profiles
16.1 Pfizer 16.1.1 Overview 16.1.2 Offerings 16.1.3 Key Financials 16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 GlaxoSmithKline plc 16.2.1 Overview 16.2.2 Offerings 16.2.3 Key Financials 16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 B Braun 16.3.1 Overview 16.3.2 Offerings 16.3.3 Key Financials 16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Cipla Limited 16.4.1 Overview 16.4.2 Offerings 16.4.3 Key Financials 16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Perk Pharmaceuticals Ltd 16.5.1 Overview 16.5.2 Offerings 16.5.3 Key Financials 16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Lupin Laboratories Ltd 16.6.1 Overview 16.6.2 Offerings 16.6.3 Key Financials 16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Teva Pharmaceuticals 16.7.1 Overview 16.7.2 Offerings 16.7.3 Key Financials 16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Novartis
16.8.1 Overview 16.8.2 Offerings 16.8.3 Key Financials 16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 AbbVie Inc
16.9.1 Overview 16.9.2 Offerings 16.9.3 Key Financials 16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Bayer Healthcare
16.10.1 Overview 16.10.2 Offerings 16.10.3 Key Financials 16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies
16.11 Dr. Reddys Labs
16.11.1 Overview 16.11.2 Offerings 16.11.3 Key Financials 16.11.4 Business Segment & Geographic Overview
16.11.5 Key Market Developments
16.11.6 Key Strategies
16.12 Mylan Pharms Inc
16.12.1 Overview 16.12.2 Offerings 16.12.3 Key Financials 16.12.4 Business Segment & Geographic Overview
16.12.5 Key Market Developments
16.12.6 Key Strategies
